An Attenuated HSV-1-Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection against Infectious Sporozoite Challenge

Rider P. J. F., Kamil M., Yilmaz I., Atmaca H. N., Kalkan-Yazici M., DOYMAZ M. Z., ...More

Vaccines, vol.10, no.2, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.3390/vaccines10020300
  • Journal Name: Vaccines
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Directory of Open Access Journals
  • Keywords: EXP1, HSV-1, Intramuscular, Liver stage, Malaria vaccine, Subcutaneous, TMP21, UIS3, VC2, Viral vector
  • Istanbul Medipol University Affiliated: No

Abstract

Here, we present the construction of an attenuated herpes simplex virus type-1 (HSV-1)vectored vaccine, expressing three liver-stage (LS) malaria parasite exported proteins (EXP1, UIS3 and TMP21) as fusion proteins with the VP26 viral capsid protein. Intramuscular and subcutaneous immunizations of mice with a pooled vaccine, composed of the three attenuated virus strains expressing each LS antigen, induced sterile protection against the intravenous challenge of Plasmodium yoelii 17X-NL salivary gland sporozoites. Our data suggest that this malaria vaccine may be effective in preventing malaria parasite infection using practical routes of immunization in humans.